BioInvent Signs Deal with Bayer HealthCare

BioInvent International AB has signed an agreement with Bayer Healthcare concerning the research and development of therapeutic antibodies. The agreement covers the development of up to 14 antibody products. It gives Bayer Healthcare, which will provide the funding, a non-exclusive research license for the use of a proprietary Bioinvent library, which will be used for the discovery of monoclonal antibodies. Bioinvent will provide access to an extended antibody technology suite, which includes its proprietary selection processes, streamlined robotics and immunoglobulin transient expression technology. Bioinvent will receive milestone payments and royalties on sales of any commercialized products in addition to the license fees.

For further information please contact:

Svein Mathisen

President & CEO

Tel: +46 (0)46-286 85 67

E-mail: svein.mathisen@bioinvent.com

Or visit: www.bioinvent.com